DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lumiliximab
Lumiliximab
Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
B-Cell Targets to Treat Antibody-Mediated Rejection In
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Newer Monoclonal Antibodies for Hematological Malignancies
I Regulations
Molecular Targeted Therapies for Indolent Lymphomas: Where Are
Tailored Therapy for Severe Asthma Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1
New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
INN Working Document 05.179 Update 2011
Transforming Discovery Into Care 2007 ANNUAL REPORT Highlights
International Nonproprietary Names for Pharmaceutical Substances (INN)
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Customs Tariff - Schedule Xxi - 1
Top View
Immunology at Biogen Idec
BIOGEN IDEC INC. (Name of Registrant As Specified in Its Charter)
Structural Basis for Selective Inhibition of Immunoglobulin E-Receptor
Lumiliximab for the Treatment of Chronic Lymphocytic Leukaemia
Highlights from the 10Th International Conference on Malignant Lymphoma: a Review of Selected Presentations
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Ofatumumab, a Second- Generation Anti-CD20 Monoclonal Antibody, For
Ph-Responsive Antibodies for Therapeutic Applications
Phase 1Study of Lumiliximab with Detailed Pharmacokinetic And
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
ATAD00086-Lumiliximab ( 鲁昔单抗)
(INN) for Biological and Biotechnological Substances
Thalidomide - Wikipedia, the Free Encyclopedia
Assessment of the Evolution of Cancer Treatment Therapies
Immunotherapy in Asthma
Biogen Idec Inc. (Exact Name of Registrant As Specified in Its Charter)
Activation of Fcγr-Dependent Responses to Therapeutic Antibodies
From Ige to Omalizumab
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
WO 2015/105926 Al 16 July 2015 (16.07.2015) P O PCT